Tissue engineering is an interdisciplinary field aimed at maintaining, restoring, and promoting the normal function of organs and tissues using biomaterials and live cells by incorporating concepts from materials science, bioengineering, biological sciences, and medicine. Biofabrication aims to produce engineered tissue constructs to repair or replace damaged or diseased human tissues with full functionalities. In this regard, the biofabrication of multifunctional and bioactive biomaterials that can replace the cellular/tissue microenvironment is critical for personalized tissue regeneration and disease modeling. This symposium will highlight recent trends in the development of biomaterials-based biofabrication strategies that play functional roles in regulating cellular behaviors and tissue regeneration. Moreover, the session will also feature frontier 3D bioprinting and stimuli-responsive materials for design of complex microenvironments, and translational strategies for taking these approaches from ‘Bench to Bedside’ for personalized disease modeling and regenerative therapies. We anticipate that our interdisciplinary session including biofabrication, tissue engineering, biomaterials, and regenerative medicine will be of great significance to scientists and engineers working in life sciences, biomedical engineering and clinical medicine.
Ischemic heart disease is a leading cause of death worldwide. Injury to the heart is followed by loss of the damaged cardiomyocytes, which are replaced with fibrotic scar tissue. Depletion of cardiomyocytes results in decreased cardiac contraction, which leads to pathological cardiac dilatation, additional cardiomyocyte loss, and mechanical dysfunction, culminating in heart failure. Many therapies have focused on preventing the progressive process of heart failure including cellular and noncellular therapies. In this session, we introduce novel therapeutic approaches using cardiac organoid/spheroids and biomaterials for in-situ cardiac regeneration, which offering the potential to control cardiac remodelling and redirect the adult heart to a regenerative state.
Regeneration of neural tissues, especially that of the central nervous system, is a significant challenge in regenerative medicine. In addition to neurons, glial cells, such as astrocytes and oligodendrocytes, also play significant roles in determining regeneration and functional outcomes. Hence, the ability to specifical-ly direct the behavior of neural cells is of therapeutic importance and relevance. Extracellular signaling plays critical roles in dictating cell fate. Besides biochemical signals from drugs, growth factors and nu-cleic acids, physical signals like matrix topography and compliance also affect cell response. This sympo-sium gathers the recent advancements in neural differentiation/transdifferentiation and/or bio-functional scaffold designs for neural tissue engineering applications.
In order to repair damaged tissue, it is important to maintain balance and homeostasis. However, the incidence of difficult-to-heal chronic wounds due to diabetic foot, arteriovenous ulcer, burn, pressure sore, etc. is rapidly increasing worldwide. Recently, various wound healing technologies including electrical stimulation, nano-complex material, natural and synthetic dressing materials and so on have been developed to overcome these problematic chronic wounds. In addition, hypertrophic scars or keloids appearing after wound healing is another important issue which can have serious clinical deformity. Studies for overcoming these scars and achieving scarless wound healing are being actively conducted. This session is intended to introduce the latest research on wound healing acceleration and avoiding scars.
Extracellular vesicles are key mediators of intercellular transfer of bioactive molecules, and have promising potential as biotherapeutics and diagnostics. This symposium will highlight opportunities and challenges for extracellular vesicle therapeutics and diagnostics in regenerative science and medicine. Key topics include isolation, scale up, characterization, storage, engineering, drug delivery, and disease-specific applications of extracellular vesicle treatment and diagnostic strategies. Speakers include leaders in the field of extracellular vesicles from industry and academia.
The ability to vascularize engineered tissues is currently one of the greatest hurdles in tissue engineering. Therefore, the research on vasculogenesis in vitro and angiogenesis in vivo are crucial for the generation of large-scale functional tissues for clinical transplantation. This will ensure the surgical integration of the engineered tissues into the patient’s own vasculature after implantation and to increase the success rate for clinical translation.
This symposium will invite experts to give keynote and invited lectures on: 1) the importance of vasculogenesis and angiogenesis on functional tissue engineering; 2) current advance in using stem cells and in vitro model for enhancing vasculagenesis; 3) in vivo models for promoting angiogenesis of tissue engineering constructs. We will also select the best abstracts submitted to this symposium for oral presentations. This symposium will add educational value for junior faculties and early career researchers to learn the importance of vasculogenesis and angiogenesis on functional tissue engineering and provide the opportunity for exchange knowledge and skill in this topic, which has great impact for translational research in regenerative medicine.
Dr Yang (University of Leeds, UK) has both clinical background in orthopaedics and expertise on stem cell therapy and tissue engineering using in vitro and in vivo models. Dr Matsusaki (University of Osaka, Japan) is an expert on functional biomaterials for tissue engineering applications. His group has developed novel 3D in vitro models for inducing blood capillary, constructing vascularized hepatic tissue and controlling of vascular network.
Dr Yang has successfully organized/chaired several symposia on osteocondral/bone tissue engineering, animal models and clinical translation topics for TERMIS-WCs 2012/2015/2021, TERMIS-AP 2013/2014/2016/2017, and TERMIS EU 2019. Both the chair and co-chair will use social media and professional societies’ mailing list(s) to encourage more people to submit high quality abstracts to this symposium.
Myocardial tissue engineering has been pursued for the last 20 years. Cell injection and cell sheet transplantation have been already clinically applied in the word, however their effects have been limited. It is because main mechanism in those therapy mainly depends on paracrine effects originated from transplanted cells. Mixture of several cytokines improve damaged hear function via neovascularization, inhibition of cell death and fibrosis. Therefore, the shortage of cardiomyocytes has not been fundamentally resolved. Recent development of human iPS cell-derived cardiomyocytes has opened new possibilities that transplanted cells might directly support the heart function. Human iPS cell-derived cardiomyocyte sheet transplantation has been just started clinically in Japan. Furthermore, functionally beating human myocardial tissues have been successfully engineered using iPS cell-derived cardiomyocytes. Mass production and maturation of these cells have been pursued and in vitro neovascularization is one of the most critical challenges for fabricating thick myocardial tissue graft which can support heart function and improving cardiac output by their-own contraction. In this symposium, recent advances in myocardial tissue engineering using human cardiomyocytes will be presented and discussed.
Extracellular signaling plays significant roles in dictating cell fate. In particular, physical signals like ma-trix topography and compliance affect cellular response. In combination with extracellular biochemical signals from drugs, growth factors and nucleic acids, synergistic effects are often seen. This symposium gathers the recent advancements in bio-functional scaffold designs that focus on imparting synergistic physical and biochemical cues to direct cellular differentiation and tissue regeneration for regenerative medicine.
In this current session, we aim to discuss cell-based tissue engineering technologies in the field of head and neck surgery, particularly focus on airway regeneration
Recently, substantial progress has been reported for tissue-engineered bone formation and its use to repair bone defects. Ideal strategies for tissue-engineered bone formation utilize optimal combinations of biodegradable three-dimensional porous scaffolds that closely mimic the natural bone extracellular matrix niche, osteoprogenitor cells that synthesize the bone tissue matrix, and biologically active growth factors that induce or promote endogenous bone and vascular formation. However, many specific procedures for the preparation of appropriate cells or biomaterials for use in therapy are still needed. The main aims in this session are to discuss cell-based or biomaterial-based tissue engineered regeneration for the reconstruction of various defects in oral and maxilofacial region, including bone and nerve.
In biosystems, cells perform their intended functions collectively by forming three-dimensional structures to evolve over time. These structures are composed of cells that operate complex physiological activities throughout active or passive cell-cell and cell-matrix interactions. Extensive research has focused on individual cells' genotypic and phenotypic activities in controlled environments engineered with biomaterials and fabrication technologies. In contrast, little is known about the extent to which cellular adhesion to neighboring cells in the 3D clusters modulates the complex morphogenesis and physiological function of engineered tissue and organs and underlying fundamental process. Such a knowledge gap has been one of the challenges towards successful tissue and organ regeneration.
We, therefore, propose a symposium that can address this grand challenge of measuring and regulating multi-cellular systems, including organoids and biological machines, that exhibit desired functionalities and perform prescribed tasks. These multicellular systems can perform sensing, information processing, actuation, protein secretion, and transport elements. We plan to invite leaders in this biophysics and fabrication field and learn how multiple cells interact to integrate their internal developmental program, determine their phenotypes, and build biosystems with physiological or pathophysiological activities. Throughout this symposium, the audience will be able to advance a fundamental understanding of cell-cell interactions and their control by biochemical and mechanical cues and understand how to predict and engineer physiologically functional tissues and organs. Therefore, this symposium will define the disciplines crucial for building new tissue and organs for a wide range of applications. Furthermore, we can construct complex systems to perform new tasks that have never been explored before.
This special session will report state-of-the-art tissue engineering and regenerative medicine applications by addressing science, engineering, development, regulatory, biomanufacturing, and clinical aspects of the field. This session will explore the translation and practical use of biofabrication, tissue engineering, and regenerative medicine strategies. The session will invite six keynote speakers who have extensive translational research expertise and experience.
Generally, TERMIS attendees who are involved in biomedical engineering, cell biology, molecular biology, and material science may well be interested in this topic, as all of these disciplines are required for the development of translational regenerative medicine products and biomanufacturing.
In this session, we aim to discuss up-to-date technologies for tissue engineering in the field of ENT, particularly biofabrication perspective.
Regenerative dentistry means the regeneration for damaged odontogenic tissues or their supporting tissues. Supporting portions of the odontogenic tissues include the alveolar bone of the alveolar processes of the maxilla and mandible, periodontal ligaments, and gingiva. Especillary, the success of dental implant in the older ages is heavily based on the healthy supporting tissues. Tissue-engineered regeneration will be discussed for the reconstruction of dentin, pulp, and periodontal ligament in this session. Also, tissue-engineered approaches for long-term success rates of implant placement will be presented.
The session focuses on various engineered biomaterials for therapeutic immune modulation. This session covers specific topics about biomaterial-mediated exogenous delivery of immune activator, immunomodulators, and biological substances. In addition, a series of immune engineering platforms such as localized imaging technology, self-assembled structures, scaffold/hydrogels for immunomodulation, material-associated cellular manipulation will be also included.
The conventional approaches in research often involve culturing of cells in two dimensional surfaces and animal models, but these were still not fully comparable to human reality/conditions and can result in misleading research data. In the last few years, standardized and high-throughput 3D human tissue in vitro models, the so-called complex in vitro models (CIVMs), has allowed bridging the gap between pre-clinical and clinical trials, by means of enabling overcome the current scientific limitations and mimic the human tissue/organ microenvironment and complexity. The main objective of the symposium on “In vitro Models: Processing techniques and applications” is to provide the attendees the latest developments in the field. A special focus will be given to: the types of CIVMs that can be envisioned, which can include spheroids and microphysiological systems including, organoids (commonly derived from stem cells or other progenitor cells), hydrogels-based in vitro models, scaffolds-based in vitro models, bioprinted of in vitro models, tissue engineered in vitro models, and in vitro models integrated in dynamic culture systems (e.g., microfluidics and bioreactors) such as organ/body-on-chip devices. The recent works related to the applications of the different in vitro models will be also presented herein, in particular in tissue engineering, drug discovery/development, neurosciences, precision medicine and cancer research. Finally, the significant achievements and the current research findings that are drivers for future investigations which can open new possibilities for the design and validation of platforms based on in vitro models will also be discussed.
The main objective of the symposium is to introduce the TERMIS community to a novel class of biofabrication approaches that intends to revolutionize the way to engineer complex multicellular systems.
Morphogenesis, a complex process, ubiquitous in developmental biology, regenerative medicine, and many pathologies, is based on self-patterning of cells. Spatial patterns of cells, organoids, inorganic particles can be forced on-demand using acoustic field-based assembly processes. Such contactless methods allow tuning parameters under fast and mild culture conditions, for morphologically relevant tissue generation.
We believe this symposium will be a unique opportunity to initiate the TERMIS community to emerging sound-wave-driven bioassembly processes which pave the way to a number of applications, ranging from the generation of advanced micro-physiological models for drug screening to novel therapeutics approaches and cell therapy fields. This symposium will attract contribution by all groups interested in Biofabrication, Biomaterials, 3D in vitro modeling. In addition, it will interest all groups investigating extrinsic forces fields and their influence on living cells and tissues.
The Cardiovascular Special Interest Group has the mission to foster the professional interaction and address the common concerns of academic and industrial scientists and engineers, clinicians, and regulatory professionals concerned with the discovery, research, development, and use of biomaterials for cardiovascular devices and implants.
Cell manufacturing is the critical step to realize the cell therapy. This symposium covers recent development of manufacturing techniques including not only development of a novel culture system but also construction of automation system and bioreactor as well as management of cell processing facility. In addition, the software to analysis and predict the cell quality and process profile are also critical tools such as monitoring and simulation to realize the stability of process in practical manufacturing.
This symposium will provide the facilitation of understanding concerning practical cell processing for therapy, supposing to gather the audiences from the broad fields including creators of cell therapy in basic researches, developers of cell manufacturing, operators and managers in cell processing facility.
Objectives: 3D bioprinting provides great potential for recapitulating the complex hierarchical structure of tissues and organs, but key challenges remain. This symposium focuses on the development of 3D bioprinting technology and testing bioprinted products in applications of tissue regeneration, disease modelling, and drug testing, with a specific focus on cardiac and musculoskeletal tissues.
Key concepts: 3D bioprinting is an area of rapid and exciting development in tissue engineering, consisting of technologies to precisely dispense cell-laden biomaterials for constructing complex and functional living tissues or organs. Compared to traditional biofabrication methods, 3D bioprinting offers unprecedented ability to print bio-constructs with precise control over their composition and spatial distribution, producing biomimetic tissue architecture and properties. Major advances in this area include the development of high-throughput and high-resolution bioprinting technologies with the capability of producing hierarchical, vascularised, thick tissue engineered constructs, as well as novel bioinks that can support native tissue function and encourage integration with host tissues. 3D bioprinting is already demonstrating its potential in generating a range of transplantable tissue constructs, as well as organoids that replicate the function and properties of native tissues, including highly vascularised tissues such as heart, cartilage and bone microtissues.
Impact and applications: Bioprinted tissues have potential to be used as transplantable grafts to repair or replace damaged tissues, as well as for the development of advanced in vitro models to study tissue pathophysiology and treatments. Despite recent developments, key challenges of current bioprinting approaches remain, such as printing resolution and precision, versatility of cell types and materials, ability to print large and hierarchical constructs, and achieving functional vascularisation and innervation. All of these topics are welcome in this symposium, from advances in the technology of bioprinting to its applications in generating artificial tissues and organs, as well as current challenges and outlook.
The properties of the native extracellular matrices (ECM) at different hierarchical scales and its microenvironment are known to play a key role on many biological functions of tissue. Therefore, tissue engineering and regenerative medicine approaches inspired in such concepts have far more potential to lead to advanced tissue substitutes or models that more closely resemble native tissue functionalities and properties. The focus of this symposium will be on emerging designs and 3D fabrication technologies with new functionalities applied in tissue engineering and regenerative medicine as well as in disease modeling. Contributions regarding the development of microfabrication techniques such as three dimensional (3D) bioprinting and advanced bioink biomaterials, but also spheroid-based 3D tissue construction for the development of biomimetic microarchitectures that reproduce the characteristics of the native ECM are of interest of this session. Additionally, this symposium foresees studies on the integration of such systems with drug delivery approaches and/or physical stimulus for achieving better control of the tissue environment and thus improved functionality.
Bioprinting is recognized as an emerging technology creating multiscale 3D architectures composed of various types of living cells and biomaterials to produce functional tissues and organs expected to be translational in the clinic. To promote scientific exchange and closer networks and collaborative ties among multidisciplinary researchers, we have invited one keynote and four distinguished speakers as new frontiers of 3D bioprinting, bioinks, and its applications in tissue engineering and regenerative medicine. This session will cover cutting-edge research and future perspectives on biofabrication-assisted tissue engineering.
Special session for career development
Musculoskeletal degeneration and incomplete recovery from injuries have become more prevalent as people live longer and increasingly participate in rigorous athletic and recreational activities. Additionally, defects in skeletal tissues may immobilize people and cause inflammation and pain, which finally lower people's quality of life and shorten their lifespan. In this session, speakers will review current knowledge, clinical applicaion and future perspectives regarding diverse musculoskeletal tissue regeneration.
Stimulated by the development of various printing technologies, biofabrication has been playing important role in various biomedical engineering. This session will cover the use of various fabrication techniques to produce complex biomedical materials or devices. Fabrication methods include 2D or 3D printing techniques, while application areas include miniaturized biosensor, tissue engineering scaffold, lab on a chip devices and other micro or nanofabricated biomedical systems.
In order to enhance the therapeutic effect and reduce the associated side effects, drug molecules should be selectively accumulated at the targert tisseu for a long time with high controllability. Smart and targerted drug delivery refers to approaches, formulations, technologies and systems for transporting therapeutic agents into the body as needed to safely and efficiently achieve a desired therapeutic effect. Currently, new concnetional desing for targeted drug delivery, such as flexiable mdeical devices, biosystem responsive molecules and etc have been tried in academica area and quickly moves to clinical areas. This session will discusss current scientific achivements for Smart and Targeted Drug Therapy.
1) Objectives: To secure source proprietary technologies and commercialization strategies in the fields of advanced tissue engineering and regenerative medicine, we would like to hold a symposium for women scientists and engineers. It aims to strengthen the continuous collaboration foundation for industry-academic research networks of domestic and international female participants.
2) Key concept and related contents: Through a plenary lecture, invited presentations, and panel discussions by excellent women scientists or engineers, we will share the latest research results, lead mentoring programs, and secure core technologies and commercialization in the fields of tissue engineering and regenerative medicine to contribute to global health.
Regenerative engineering aims to develop functional, bioactive, and instructive biomaterials and approaches for the regeneration of tissues through a convergence of engineering, medicine, developmental biology, and stem cell science. This symposium will highlight recent trends in developing functional biomaterials that play an active role in controlling cellular behaviors and tissue regeneration. During the symposium, translational strategies for handling these biomaterials from ‘Bench to Bedside’ will also be addressed.
Osteoarthritis (OA) is a chronic, prevalent, debilitating joint disease characterized by progressive cartilage degradation, subchondral bone remodeling, bone marrow lesions, meniscal damage, and synovitis. OA is directed toward symptomatic treatment, mainly pain management, and is not able to promote regeneration of degenerated cartilage or to attenuate joint inflammation. Since articular cartilage have no ability to heal, regeneration of cartilage injury remains one of the most important goals of new therapeutic approaches used for OA treatment. In this session, speakers will review current knowledge, clinical applicaion and future perspectives regarding cell therapy for cartilage repair and the treatment of OA.
Light based bioprinting has been actively investigated as one of the enabling technologies for the impending era of personalized medicine. These technologies, which use light for polymerization of biomaterials, have made significant progress in the quality, resolution and generation of precise complex tissue structures. Numerous fields have been disrupted by its introduction, such as tissue engineering and regenerative medicine. This is often attributed to the technology’s inherent versatility, unique ability to fabricate intricate designs, and cost-effectiveness compared to traditional manufacturing processes. This symposium will focus on the most common light-based technologies using photopolymerization including, Laser-based SLA, Mask-based SLA, Digital Light Projection (DLP), two-photon bioprinting (TTP), laser induced forward transfer (LIFT), laser-direct bioprinting (LDP), Volumetric 3D printing and any other novel light based bioprinting and biofabrication approaches; and their application to tissue engineering and regenerative medicine. In recent years, the evolution of these technologies has been growing along with the development of new photocurable resins and photoinitiators that are biocompatible and biodegradable with bioactive properties. Such evolution has allowed the progress of a large number of tissue engineering applications. With the broad application of 3D microstructures in the biomedical field, this symposium will also pay attention to the physicochemical properties of the resulting tissue structures, such as biocompatibility, biodegradability, stimuli responsiveness and immunogenicity.
The field of hydrogels for TERM applications is a prolific area of research with applications for most bodily tissues. Over the last decade, scientists have incorporated biological (growth factors, cytokines) and biophysical (substrate topography, material stiffness, degradable sequences) cues as a mean to better understand cell/scaffold interactions as well as enhancing therapeutic outcomes.
With this symposium, we aim to gather scientists and clinicians to address these new developments and highlight both basic science studies and recent translational applications. For this we have invited renowned researchers in the field who will share their work on different aspects related to hydrogels and cell fate.
The keynote presentations will showcase recent advances, covering both chemical and biological aspects of the design of biofunctionalized hydrogels, that are able to recapitulate some of the fundamental cues of native environments to drive the local tissue regeneration. More specifically, the keynote speakers will focus on recent regenerative applications of hydrogels on understanding and controlling stem/progenitor cell fate, as well as in vivo neural tissue regeneration. (Prof. Sing Yian CHEW, Singapore).
All in all, with this symposium we would like to provide an overview picture of the latest advancements regarding the use of hydrogels for tissue repair. This symposium will target a diverse audience of students and young scientists, as well as experts from both academia and industry, working in the field of biomedical hydrogels.
There is a shortage of tissues and organs for patients who suffer damage or loss of their tissues and organs. Stem cells hold promise for drug discovery and regenerative medicine. We would like to propose the symposium of “Biomaterials for Stem Cell Culture and Differentiation for Stem Cell Therapy”. The development of a fully defined microenvironment for culturing and differentiating human stem cells will have a great effect on the use of stem cells in cell therapy and tissue engineering. In this symposium, we will discuss the design and strategy of biomaterials for stem cell culture and differentiation. Especially, we will discuss biomaterial design and preparation that can not only maintain the pluripotency and stemness of human stem cells, but also guide differentiation of stem cells (adult stem cells, fetal stem cells, human embryonic stem cells and human induced pluripotent stem cells) into specific lineages of cells (osteoblasts, chondrocytes, adipocytes, mesenchymal stem cells (from human pluripotent stem cells), hematopoietic stem cells (from human pluripotent stem cells), retinal pigment epithelium (from human pluripotent stem cells) and cardiomyocytes). We will further focus on the effects of physical cues (elasticity, micropatterning, electrical field and mechanical force), together with the biomaterials used in clinical application using stem cells and the translational development of stem cell therapies in various catastrophic illnesses including COVID-19 infection treated by hematopoietic stem cells.
Recent advances in the patient stem cell-derived 3D human organoids have been used to study vairous diseases, including genetic disorders, degenerative diseases, and cancers, and provide researchers with new opportunities to understand the pathophysiology of the diseases. In this session, we aim to introduce the recent findings on patient-derived 3D organoid platforms to simulate various disease modelings in vitro.
The key concept of this symposium is that several molecules or compounds of natural origin are of great i nterest to add specific surface functionalities to implant biomaterials. Phenolic compounds, proteins, vitam ins, essential oils, polymers derived from plants or animals can be used for different targets. The modified surfaces can have ability to enhance and fast the tissue integration, to fight or to reduce the risk of infectio ns, to guide the tissue growth, to modulate the inflammatory response, as an example.
Different strategies can be followed for modifying the surface: grafting of a molecular monolayer (functio nalization), thin or thick continuous coatings. Different substrates (metals, ceramics, glasses, polymers) ca n be used and pre-treatments can be eventually needed to make the surface suitable to chemically link the natural molecules or compounds. The selection of the processing way must be guided by the chemistry of the surface and ligands as well as by the expected mechanism of action of the biomolecule: progressive rel ease or permanent link to the surface. Functionalization or coating can be coupled to different surface topo graphy of the substrate for a synergic chemical-physical effect on the host response.
New experimental techniques and characterization protocols are needed for these surfaces in order to test t he effective presence of the biomolecules, the action in biological environments, and to understand the inv olved mechanisms. Post-processing (packaging, sterilization, storage) of the final products must be adapte d to the presence of the biomolecules, too.
The objective of the symposium is to create a chance for researchers to share their scientific expertise abou t this topic and to dialogue with the industrial manufacturers of implants about the potentiality of this appr oach for a future generation of products. Potential applications are in orthopedic, dental, cardiovascular im plants.
The 2022 TERMIS-AP Congress will be held in Jeju island, South Korea from Oct May 5 to 8, 2022. This meeting plans to invite the experts of reproductive tissue engineering to the section of “Regeneration of Reproductive Tissues and Organs”. This session emphasizes on the recent scientific issues for communications and networking of particular interests among the community which includes focused presentations with high interest regarding emerging topics. Reproductive tissues are essential the fertility, which needs new engineering approaches to overcome the current therapeutic limitations. This session will be the sharing moment of findings newly made and inspire the many researchers working in this emerging field.
Gene editing by CRISPR and gene regulation by microRNA or CRISPR activation have dramatically changed the way to manipulate cellular gene expression and cell fate. In recent years, various gene editing and gene manipulation technologies have been applied to control stem cell differentiation to enhance tissue regeneration. The primary objective of this symposium is to bring researchers in the gene editing and gene regulation field together to present their research in the application of these burgeoning technologies in stem cell differentiation. This symposium welcomes presentations in the topics of CRISPR, CRISPR activation (CRISPRa), CRISPR inhibition (CRISPRi), RNAi, microRNA, long non-coding RNA and all relevant technologies and their applications to control cell differentiation and tissue regeneration. We expect that this symposium can promote the exchange of new ideas and advancement of regenerative medicine. This is a new field that is very hot in Europe and the US. The main organizer Prof. Yu-Chen (Andy) Hu is the Program Chair of TERMIS-AP, 2016. Prof. Hu is not only experienced in organizing conferences and symposiums, but also well connected with experts in these fields. We will invite speakers from Europe and the US, hoping that the symposium can also promote the collaborations between researchers in TERMIS-AP, TERMIS-EU and TERMIS-AM.
Human patient stem cell-derived 3D organoids have shown to provide a regenerative potential for vairous diseases, including genetic disorders, degenerative diseases, and cancers, and provide researchers with new opportunities to regenerate the the diseases. In this session, we aim to introduce the recent findings on how patient-derived 3D organoids could regenerate various diseases.
☆ FTERM open session discussion For all participants Halla Hall ☆
In open discussion panel session, the audience are invited to ask questions within this topic (How can TERMIS make a real impact on regenerative medicine within the next 10 years) to the fellows.
We would like to make this session as interactive as possible and are happy for audience participation.
R.Geoff Richards, Chair of the FTERM
INTERNATIONAL FELLOWS OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE (FTERM)
The International Fellows of Tissue Engineering and Regenerative Medicine (FTERM) was created to recognize a distinguished leader within the tissue engineering and regenerative medicine field. FTERM was established to recognize an individuals role in shaping the tissue engineering and regenerative medicine field and TERMIS.
• Honorary status to recognize individuals that have made outstanding contributions to the field of TERM, with outputs of clear professional excellence.
• The distinguished members of TERMIS that are recognized as Fellows should be role models for members of the Society and others in the field.
• Fellows are expected to foster new activities and continue to act as leaders in the field, supporting its development.
FTERM Panel
Prof Geoff Richards (Past President and chair of the International Fellows of TERMIS (FTERM))
Prof. Mauro Alini
Prof. Manuela Gomes
Prof. Rui L. Reis (Past chair of FTERM)
Prof. Abhay Pandit
Prof Yasahiko Tabata
Prof. Jin Ho lee
Prof. Hai Bang Lee
https://termis.org/international-fellows-tissue-engineering-and-regenerative-medicine-fterm
Nanomedicine is the use of nanomaterials in medicine. Nanomaterials are broadly defined as materials with at least one dimension less than 100 nm. Due to their small size, nanomaterials can have higher surface energy, penetrate tissues and cells, and can avoid immune system clearance to last longer in the circulatory system. Nanomedicine has already revolutionized disease prevention, diagnosis, and treatment across many parts of healthcare. Diseases in which nanomedicine has impacted medicine include COVID-19 (through the development of vaccines), cancer, diabetes, infection, and tissue engineering. The objective of this symposium is to highlight the recent advances that nanomedicine has made towards improving the design, testing, and use of tissue engineered materials to treat a wide range of diseases. It will highlight various nanomaterials including particles, tubes, fibers, meshes, and other structures. It will also highlight various state-of-the-art manufacturing processes, such as 3D and 4D printing, electrospinning, polymer extrusion, and more. It seeks to also emphasize post-processing nanotexturing such as the use of atomic layer deposition, chemical etching, embedding nanoparticles, e-beam lithography, and more that have been shown to control cell responses. Up-and-coming future areas of nanomedicine will also be emphasized such as the incorporation in implantable sensors into tissue engineering materials to monitor and control tissue healing. Lastly, this symposium will highlight various medical applications including orthopedics, cardiovascular, neurological, cancer, infection, etc. As such, this symposium will highlight an up-and-coming area of tissue engineering and regenerative medicine in nanomedicine providing critical data for the field to continue to grow.
Induced pluripotent stem cells (iPSCs) provide immune-compatible autologous replacement tissue for the treatment of potentially all degenerative diseases. Several groups are interested in developing autologous and allogeneic iPSC based therapies for degenerative diseases. However, major challenges remain in translating these therapies into clinic. There are challenges to develop clinical grade iPSC lines, how to quality control them and test the derived product for preclinical and clinical use. The main goal of this symposium is to discuss approaches various groups are taking to develop a regulatory compliant path to develop an IPSC based cell therapy and highligh some of the major challenges that lie ahead of us.
Investigators will get an opportunity to know the current methodologies and technologies for developing and using biomaterial-based matrices for 3D cellular and cancer/disease models. In vitro 3D cell culture techniques mimic in vivo tissue microenvironment. The scaffolds are explored to develop highly realistic 3D in vitro tumor/disease models for therapeutic screening and studying disease microenvironment dynamics. Technologies will provide a means to engineer in vitro tumor/disease microenvironment and cell migration to study cancer and other diseases. Advances in scaffold/matrices fabrications using natural and blend materials, 3D bioprinting using bio-ink, micro-patterning, bio-detection/biosensing of cancer diagnostics, and microfluidic devices for the study of cell migrations (e.g. tumor cell invasion, intravasation, and extravasation), tissue growth, including properties of biomaterial matrices, like detection and imaging materials are also within the scope. The state-of-art of emerging technologies to deeper investigate cancer/disease and/or innovative treatments using in vitro 3D models are the demand of the current edge and of practical uses for therapies will be discussed.
Graduate and postgraduate students and experienced researchers in biotechnology and biomedical engineering working in natural or synthetic biomaterials, drug deliveries, emerging technologies, tissue engineering and regenerative medicine applied to cancer/diseases and/or development comprises the audience of this symposium. Those are working with natural and micro-nano composite biomaterials, in vitro microenvironment modulations, 3D cell culture, cell-based bio-inks, 3D tumor/disease modeling, nanoparticle-based delivery vehicle, micro-patterning, and drug screening using emerging technologies like microfluidics, bio-printing, tumor lab-on-a chip, spheroids, organoids and micro-tissues.
Induced pluripotent stem cells (iPSCs) and biomaterial-based approaches have shown significant promise in regenerating and repairing the injured organs including heart, brain, spinal cord and pancreas. Even though the field remains in a relative infancy, everyday researchers, engineers and clinician scientists worldwide are reporting newer industrially and clinically relevant applications of next-generation biomaterials, iPSCs and adult stem cells. In fact, in the last 5-10 years, the field of iPSCs has witnessed a significant growth in terms of disease modeling, drug development and cell-based therapies. One of the strengths of iPSC-based cell therapies is that these cells are able to differentiate into different types of somatic cells and cover the loss of dead cells after transplantation to the injured organ in the recipient. More recently, iPSC and adult stem cell derived exosomes are also reported to hold potential in initiating the repair process in the host tissue. However there have been several challenges reported in taking iPSC-based therapies toward clinical applications. Some of these challenges are, differentiation potential, immature nature of iPSC derived somatic cells, immunogenicity after transplantation, and teratoma formation. Interestingly biomaterials-based strategies have been able to overcome some of these challenges. However, in order to develop clinically relevant biomaterial-based strategies to mitigate challenges associated with clinical translation of stem cell therapies, it is very important to improve synthesis and characterization strategies to produce need-based and tailored biomaterials. Furthermore, it is very critical to understand how biomaterials work and interact with cells and tissues in our body. Based on these facts, the talks and presentations in this symposium from experts in the field will focus on challenges involved in stem cell reprogramming, differentiation, stem cell derived exosomes-based therapies. The symposium will also cover rational design, synthesis of next-generation biomaterials and application in different biological fields such as regenerative medicine, immunology and cell-based therapies.
The purpose of this symposium is to highlight key advances in the field of tumor engineering, specifically with regard to the use of biomaterials engineering and other enabling technologies to develop patient tumor avatars either using the bottom-up or top-down approach. Examples of talks that might be featured include efforts to develop complex cancer organoid-based models to recapitulate the stromal compartment of tumors, models which incorporate the immune contexture of patient tumors for the assessment of immunotherapies, as well as the use of microfluidics to enhance the viability of tumor slice cultures. This symposium will ideally showcase the latest developments in the field of tumor engineering, and serve as a platform to collate ideas and collaborations to advance how we can develop and leverage these models for personalizing cancer medicine and drug development.